In recent trading, shares of Quest Diagnostics, Inc. (Symbol: DGX) have crossed above the average analyst 12-month target price of $159.00, changing hands for $160.14/share. When a stock reaches the ...
CEO Lishan Aklog highlighted a strong close to 2024 and an optimistic start to 2025, driven by advancements in EsoGuard sales channels, reimbursement milestones, and increased clinical evidence. He ...
The average one-year price target for Co-Diagnostics (NasdaqCM:CODX) has been revised to $38.25 / share. This is an increase of 2,900.00% from the prior estimate of $1.28 dated December 18, 2025. The ...
CEO Jim Davis reported a nearly 15% revenue growth for Q4, including 5% organic growth, and close to 7% revenue growth for the full year, supported by eight acquisitions. He highlighted the Advanced ...
Investing.com - Ascendiant Capital has raised its price target on Lucid Diagnostics Inc (NASDAQ:LUCD) to $8.25 from $8.00 while maintaining a Buy rating on the stock. This target represents a ...
DUBLIN--(BUSINESS WIRE)--The "Global Epifluidic Diagnostics Technology Advancements and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research service examines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results